search
Back to results

Effects of Insomnia on Simulated Driving (MK-0000-183-00)

Primary Purpose

Insomnia

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Placebo/ethanol (blinded)
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Insomnia focused on measuring insomnia, insomniacs, simulated driving, alcohol, ethanol

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria A patient or subject may participate in the study if, at least, the ALL of the criteria below are met.

The participant:

  • Is a male or female of non-childbearing potential and 65 years of age or older at prestudy (screening);
  • Has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months prior to screening;
  • Has a current valid driver's license;
  • Their regular bedtime is between 9 pm (21:00) and 12 am (00:00);
  • During the study, are willing to refrain from napping;

Additionally, a primary insomnia patient must meet the following inclusion criteria:

  • Has a diagnosis of Primary Insomnia;
  • Reports total sleep time of < 6 hours on at least 3 out of 7 nights each week during the 4 weeks prior to screening;
  • Reports spending 6 to 9 hours nightly in bed on at least 3 out of 7 nights each week during the 4 weeks prior to screening.

Exclusion Criteria :

A patient may not participate in the study if ANY of the criteria below (among others determined by the study staff) apply.

The participant:

  • Has visual or auditory impairment;
  • Has a history of clinically significant endocrine (including diabetes), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases;
  • Has a history of neoplastic disease ;
  • Is taking, or plans to take, one or more of the following medications (non-inclusive), within the 2 weeks prior to screening and throughout the course of the study: Centrally acting anticholinergics or antihistamines; Melatonin; Anticonvulsants; Antipsychotics; Anxiolytics; Benzodiazepines; Hypnotics; Any CNS depressants; Over-the-counter medications that could affect sleep; Stimulants; Diet pills; Anti-depressants; Disulfiram;
  • Has a positive screening urine drug test (e.g., positive for benzodiazepines, cannabinoids, cocaine, etc.);
  • Has a lifetime history of bipolar disorder, a psychotic disorder, or posttraumatic stress disorder or a psychiatric condition requiring treatment with a prohibited medication; or other current psychiatric condition that, in the investigator's opinion, would interfere with the subject/patient's ability to participate in the study ;
  • Has evidence of suicidality;
  • Has a history of transmeridian travel (across > 3 time zones or > 3 hour time difference) within two weeks prior to screening or anticipates transmeridian travel during the study;
  • Has a history of shift work (defined as permanent night shift or rotating day/night shift work) within the past two weeks prior to screening or anticipates need to perform shift work during the study;
  • Has a history or diagnosis of any of following conditions, in the opinion of the investigator: Narcolepsy; Cataplexy (familial or idiopathic); Circadian Rhythm Sleep Disorder; Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and REM behavior disorder; Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome, central alveolar hypoventilation syndrome); Periodic Limb Movement Disorder; Restless Legs Syndrome; Primary Hypersomia; Excessive Daytime Sleepiness (EDS), not attributable to Primary Insomnia
  • Has a recent and/or active history of a confounding neurological disorder, including but not limited to: seizure disorder, stroke, transient ischemic attack, multiple sclerosis, cognitive impairment, or significant head trauma with sustained loss of consciousness and residual impairment within the last 10 years;
  • Has a history of allergy, exceptional sensitivity, or adverse reaction to alcohol;
  • Has a significant history of motion sickness or demonstrates significant simulator sickness during practice drives at screening;
  • Consumes excessive amounts of alcohol or subject or patient consumes alcohol to promote sleep (i.e., within 3 hours before going to bed);
  • Has never consumed alcohol;
  • Consumes excessive amounts of coffee, tea, cola, or other caffeinated beverages.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Primary insomnia patients and healthy subjects

    Arm Description

    Elderly participants, including primary insomnia patients and healthy subjects

    Outcomes

    Primary Outcome Measures

    Simulated driving variables
    Simulated driving variables which may include (standard deviation of lane position (SDLP), speed deviation, lane excursions, or a composite score of several driving variables).

    Secondary Outcome Measures

    Full Information

    First Posted
    September 24, 2010
    Last Updated
    June 10, 2019
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01209728
    Brief Title
    Effects of Insomnia on Simulated Driving (MK-0000-183-00)
    Official Title
    A Randomized Clinical Trial to Study the Effects of Simulated Driving on Primary Insomniacs
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    October 1, 2010 (Actual)
    Primary Completion Date
    September 1, 2011 (Actual)
    Study Completion Date
    September 1, 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a double-blind, parallel design study in elderly primary insomnia patients and demographically matched controls. The objectives if this study are primarily: 1. To determine if functional deficits in simulated driving performance can be demonstrated in primary insomnia patients, and detected in healthy volunteers, impaired by alcohol; and secondarily: 2. To compare simulated driving performance deficits in elderly primary insomnia patients to those in healthy elderly volunteers impaired by alcohol, for at least one of the following driving endpoints: standard deviation of lane position (SDLP), standard deviation of speed (speed deviation), lane excursions, and a driving composite score.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Insomnia
    Keywords
    insomnia, insomniacs, simulated driving, alcohol, ethanol

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    76 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Primary insomnia patients and healthy subjects
    Arm Type
    Experimental
    Arm Description
    Elderly participants, including primary insomnia patients and healthy subjects
    Intervention Type
    Other
    Intervention Name(s)
    Placebo/ethanol (blinded)
    Other Intervention Name(s)
    Placebo or ethanol (blinded)
    Intervention Description
    Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
    Primary Outcome Measure Information:
    Title
    Simulated driving variables
    Description
    Simulated driving variables which may include (standard deviation of lane position (SDLP), speed deviation, lane excursions, or a composite score of several driving variables).
    Time Frame
    Evaluated on, up to, 3 different days, with 2 driving sessions of ~65 minutes each day.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria A patient or subject may participate in the study if, at least, the ALL of the criteria below are met. The participant: Is a male or female of non-childbearing potential and 65 years of age or older at prestudy (screening); Has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months prior to screening; Has a current valid driver's license; Their regular bedtime is between 9 pm (21:00) and 12 am (00:00); During the study, are willing to refrain from napping; Additionally, a primary insomnia patient must meet the following inclusion criteria: Has a diagnosis of Primary Insomnia; Reports total sleep time of < 6 hours on at least 3 out of 7 nights each week during the 4 weeks prior to screening; Reports spending 6 to 9 hours nightly in bed on at least 3 out of 7 nights each week during the 4 weeks prior to screening. Exclusion Criteria : A patient may not participate in the study if ANY of the criteria below (among others determined by the study staff) apply. The participant: Has visual or auditory impairment; Has a history of clinically significant endocrine (including diabetes), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases; Has a history of neoplastic disease ; Is taking, or plans to take, one or more of the following medications (non-inclusive), within the 2 weeks prior to screening and throughout the course of the study: Centrally acting anticholinergics or antihistamines; Melatonin; Anticonvulsants; Antipsychotics; Anxiolytics; Benzodiazepines; Hypnotics; Any CNS depressants; Over-the-counter medications that could affect sleep; Stimulants; Diet pills; Anti-depressants; Disulfiram; Has a positive screening urine drug test (e.g., positive for benzodiazepines, cannabinoids, cocaine, etc.); Has a lifetime history of bipolar disorder, a psychotic disorder, or posttraumatic stress disorder or a psychiatric condition requiring treatment with a prohibited medication; or other current psychiatric condition that, in the investigator's opinion, would interfere with the subject/patient's ability to participate in the study ; Has evidence of suicidality; Has a history of transmeridian travel (across > 3 time zones or > 3 hour time difference) within two weeks prior to screening or anticipates transmeridian travel during the study; Has a history of shift work (defined as permanent night shift or rotating day/night shift work) within the past two weeks prior to screening or anticipates need to perform shift work during the study; Has a history or diagnosis of any of following conditions, in the opinion of the investigator: Narcolepsy; Cataplexy (familial or idiopathic); Circadian Rhythm Sleep Disorder; Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and REM behavior disorder; Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome, central alveolar hypoventilation syndrome); Periodic Limb Movement Disorder; Restless Legs Syndrome; Primary Hypersomia; Excessive Daytime Sleepiness (EDS), not attributable to Primary Insomnia Has a recent and/or active history of a confounding neurological disorder, including but not limited to: seizure disorder, stroke, transient ischemic attack, multiple sclerosis, cognitive impairment, or significant head trauma with sustained loss of consciousness and residual impairment within the last 10 years; Has a history of allergy, exceptional sensitivity, or adverse reaction to alcohol; Has a significant history of motion sickness or demonstrates significant simulator sickness during practice drives at screening; Consumes excessive amounts of alcohol or subject or patient consumes alcohol to promote sleep (i.e., within 3 hours before going to bed); Has never consumed alcohol; Consumes excessive amounts of coffee, tea, cola, or other caffeinated beverages.

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
    IPD Sharing URL
    http://engagezone.msd.com/ds_documentation.php
    Citations:
    PubMed Identifier
    26240742
    Citation
    Simen AA, Gargano C, Cha JH, Drexel M, Bautmans A, Heirman I, Laethem T, Hochadel T, Gheyle L, Bleys K, Beals C, Stoch A, Kay GG, Struyk A. A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone. Ther Adv Drug Saf. 2015 Jun;6(3):86-97. doi: 10.1177/2042098615579314.
    Results Reference
    result

    Learn more about this trial

    Effects of Insomnia on Simulated Driving (MK-0000-183-00)

    We'll reach out to this number within 24 hrs